Finance

Lists
Why is 069620 up 2,57%?
Dive Deeper
069620:KRX
Daewoong Pharma
107 700,00 KRW
+2,57%
(+2 700,00) 1D
19 ოქტ, 11:58:35 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 069620...
Open
105 300 KRW
High
108 500 KRW
Low
104 000 KRW
Mkt. cap
1,25 ტრლ.
Avg. vol.
19,18 ათ.
Volume
8,20 ათ.
Dividend
0,56%
Quarterly dividend
150 KRW
Ex-dividend date
27 დეკ. 2023
P/E ratio
6,34
52-wk high
199 400 KRW
52-wk low
101 900 KRW
EPS
16 988 KRW
Shares outstanding
11,59 მლნ.
No. of employees
2 ათ.
Open
105 300 KRW
High
108 500 KRW
Low
104 000 KRW
Mkt. cap
1,25 ტრლ.
Avg. vol.
19,18 ათ.
Volume
8,20 ათ.
Dividend
0,56%
Quarterly dividend
150 KRW
Ex-dividend date
27 დეკ. 2023
P/E ratio
6,34
52-wk high
199 400 KRW
52-wk low
101 900 KRW
EPS
16 988 KRW
Shares outstanding
11,59 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia
About Daewoong Pharma
CEOSeongsoo Park | ჩენგ-ჯეი ლი
Employees1,89 ათ.
Founded1945
Headquarters-
SectorPharmaceutical industry
Websitedaewoong.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
411,83 მლრ.
397,12 მლრ.
377,80 მლრ.
448,46 მლრ.
Cost of goods sold
198,11 მლრ.
185,96 მლრ.
196,61 მლრ.
199,39 მლრ.
Cost of revenue
198,11 მლრ.
185,96 მლრ.
196,61 მლრ.
199,39 მლრ.
Research and development expenses
8,31 მლრდ.
139,98 მლრ.
16,11 მლრდ.
14,81 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
144,21 მლრ.
23,12 მლრდ.
136,65 მლრ.
154,92 მლრ.
Operating expense
156,83 მლრ.
169,10 მლრ.
158,98 მლრ.
181,01 მლრ.
Total operating expenses
354,94 მლრ.
355,06 მლრ.
355,59 მლრ.
380,40 მლრ.
Operating income
56,89 მლრდ.
42,06 მლრდ.
22,21 მლრდ.
68,07 მლრდ.
Other non operating income
-1,16 მლრდ.
2,77 მლრდ.
1,52 მლრდ.
-36,53 მლრდ.
EBT including unusual items
54,73 მლრდ.
68,97 მლრდ.
33,97 მლრდ.
21,89 მლრდ.
EBT excluding unusual items
54,73 მლრდ.
88,02 მლრდ.
11,82 მლრდ.
21,89 მლრდ.
Income tax expense
7,42 მლრდ.
-16,73 მლრდ.
8,46 მლრდ.
1,98 მლრდ.
Effective tax rate
13,56%
-24,26%
24,89%
9,02%
Other operating expenses
1,17 მლრდ.
1,17 მლრდ.
1,88 მლრდ.
1,61 მლრდ.
Net income
46,37 მლრდ.
89,84 მლრდ.
25,90 მლრდ.
33,37 მლრდ.
Net profit margin
11,26%
22,62%
6,86%
7,44%
Earnings per share
-
-
-
-
Interest and investment income
-
1,12 მლრდ.
1,74 მლრდ.
-
Interest expense
-
-3,53 მლრდ.
-8,00 მლრდ.
-
Net interest expenses
-
-2,41 მლრდ.
-6,26 მლრდ.
-
Depreciation and amortization charges
1,77 მლრდ.
1,43 მლრდ.
1,15 მლრდ.
7,94 მლრდ.
EBITDA
69,45 მლრდ.
56,04 მლრდ.
38,38 მლრდ.
92,95 მლრდ.
Gain or loss from assets sale
-12,80 მლნ.
-52,31 მლრდ.
35,01 მლნ.
-7,54 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები